title: [Prostacyclin derivatives].
abstract: Epoprostenol (prostacyclin) has been shown to improve survival in pulmonary arterial hypertension. However, this therapy needs continuous intravenous administration devises because of its short half-life. Recently, an orally active prostacyclin analogue, beraprost sodium, and its drug delivery system have been developed in Japan. Beraprost sodium improves pulmonary hemodynamics in patients with pulmonary arterial hypertension. In addition, we have developed ONO-1301, a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Subcutaneous administration of ONO-1301 markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. These prostacycline derivates may be promising for the treatment of pulmonary arterial hypertension.
authors.affiliation: Nagaya Cardiovascular and Respiratory Clinic
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Nagaya
mesh_terms: D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use
chemical_list: D011725:Pyridines; C105488:ONO 1301; C048081:beraprost; D011464:Epoprostenol